Antiarrhythmic drug therapy for atrial fibrillation: Are the guidelines guiding clinical practice?

Clinical Cardiology

Volumn 29, Issue 3, 2006, Pages 97-102

  Reiffel, James A ^a   Naccarelli, Gerald V ^b  

^a NewYork Presbyterian Hospital   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Amiodarone; Antiarrhythmic drugs; Class IC drugs; Propafenone sustained release; Rhythmol SR Atrial Fibrillation Trial; Structural heart disease

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DISOPYRAMIDE; DIURETIC AGENT; DOFETILIDE; FLECAINIDE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SIMVASTATIN; SOTALOL; WARFARIN;

ALGORITHM; BLINDNESS; CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERABILITY; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART RHYTHM; HIGH RISK PATIENT; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LIVER TOXICITY; LUNG TOXICITY; NEUROPATHY; PATIENT COMPLIANCE; PHOTOSENSITIVITY; PRACTICE GUIDELINE; QT PROLONGATION; REVIEW; RISK FACTOR; SINUS BRADYCARDIA; SKIN TOXICITY; SURVIVAL; TORSADE DES POINTES; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DRUG UTILIZATION REVIEW; ELECTROCARDIOGRAPHY; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PRODUCT SURVEILLANCE, POSTMARKETING; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 33645089446     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960290303     Document Type: Review

References (29)

1. Falk RH: Atrial fibrillation. N Engl J Med 2001;344:1067-1078
2. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators: A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-1833
3. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma Said SA, Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ: Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group: A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-1840
4. Prystowsky EN, Margiotti R, Fogel R, Evans JJ, Freedberg N, Shaar C: Atrial fibrillation with and without heart disease: Clinical characteristics and proarrhythmic risk (abstr 1109). Circulation 1996(suppl 8);94:1
5. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG, Gibbons RJ, Antman EM, Alpert JS, Faxon D, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Russell RO, Smith SC Jr, Klein WW, Alonso-Garcia A, Blomstrom-Lundqvist C, de Backer G, Flather M, Hradec J, Oto A, Parkhomenko A, Silber S, Torbicki A; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation); North American Society of Pacing and Electrophysiology: ACC/AHA/ESC Guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation). Circulation 2001;104:2118-2150
6. Pritchett EL, Page RL, Carlson M, Undesser K, Fava G; Rythmol Atrial Fibrillation Trial (RAFT) Investigators: Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. Am J Cardiol 2003;92:941-946
7. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ: Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 1999;341:857-865
8. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN, for the Department of Veterans Affairs CHF-STAT Investigators: Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: Observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). Circulation 1998;98:2574-2579
9. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, Massie BM, Colling C, Lazzeri D: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia: Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995; 333:77-82
10. Julian DG, Jackson FS, Szekely P, Prescott RJ: A controlled trial of sotalol for 1 year after myocardial infarction. Circulation 1983;67:161-162
11. Kober L, Bloch Thomsen PE, Moller M, Torp-Pedersen C, Carlsen J, Sandow E, Egstrup K, Agner E, Videbaek J, Marchant B, Camm AJ, Danish Investigations of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group: Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: A randomized trial. Lancet 2000;356: 2052-2058
12. Cardiac Arrhythmia Suppression Trial (CAST) Investigators: Preliminary report: Effects of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321:406-412
13. Teo KK, Yusuf S, Furberg CD: Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. J Am Med Assoc 1993;270:1589-1595
14. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE: Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. J Am Med Assoc 2001;285:2370-2375
15. Zimetbaum P, Ho KK, Olshansky B, Hadjis T, Lemery R, Friedman PA, Cannom DS, Chen XH, Josephson ME, FRACTAL Investigators: Variation in the utilization of antiarrhythmic drugs in patients with new onset atrial fibrillation. Am J Cardiol 2003;91:81-83
16. The AFFIRM Investigators: Atrial Fibrillation Follow-up Investigation of Rhythm Management. Baseline characteristics of patients with atrial fibrillation: The AFFIRM study. Am Heart J 2002;143:991-1001
17. IMS: NPA Audit, 2004
18. Fang MC, Stafford RS, Ruskin JN, Singer DE: National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med 2004;164:55-60
19. Heart Rhythm Society: Heart Rhythm Foundation Rx Survey. Current Usage of Cardiac Drugs. August 2004
20. Vorperian VR, Havighurst TC, Miller S, January CT: Adverse effects of low dose amiodarone: A meta-analysis. J Am Coll Cardiol 1997;30:791-798
21. Kochiadakis GE, Igoumenidis NE, Hamilos MI, Tzerakis PG, Klapsinos NC, Zacharis EA, Vardas PE: Long-term maintenance of normal sinus rhythm in patients with currently symptomatic atrial fibrillation: Amiodarone vs. propafenone. Both in low doses. Chest 2004;125:377-383
22. Connolly SJ: Evidence-based analysis of amiodarone efficacy and safety. Circulation 1999;100:2025-2034
23. Siddoway LA: Amiodarone: Guidelines for use and monitoring. Am Fam Physician 2003;68:2189-2196
24. Raeder EA, Podrid PJ, Lown B: Side effects and complications of amiodarone therapy. Am Heart J 1985;109:975-983
25. Jafari-Fesharaki M, Scheinman MM: Adverse effects of amiodarone. Pacing Clin Electrophysiol 1998;21:108-120
26. Holmes JS, Shevrin M, Goldman B, Share D: Translating research into practice: Are physicians following evidence-based guidelines in the treatment of hypertension? Med Care Res Rev 2004;61:453-473
27. Aliyu ZY, Yousif SB, Plantholt K, Salihu HM, Erinle A, Plantholt S: Assessing compliance of cardiologists with the National Cholesterol Education Program (NCEP) III guidelines in the ambulatory setting. Lipids Health Dis 2004;12:3:9
28. Nair A, Hazell W, Sutton T, Pillai S: Antithrombotic therapy in atrial fibrillation: An assessment of compliance with guidelines. N Z Med J 2005;118: U1258
29. Komajda M, Lapuerta P, Hermans N, Gonzalez-Juanatey JR, van Veldheuisen GJ, Erdman E, Tavazzi L, Poole-Wilson P, Le Pen C: Adherence to guidelines as a predictor of outcome in chronic heart failure: The MAHLER survey. Eur Heart J 2005;26:1653-1659